Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The compound was originally developed by Eli Lilly and licensed to Innovent Biologics for development and commercialization in China
Clinical Trial Results: Weight Loss & Key Outcomes Phase 2 (Published in NEJM & Nature Medicine) Obesity trial (NEJM 2023): Up to 24.2% mean weight loss at 48 weeks (12 mg dose)
Choi, B
Both drugs are GLP-1s, but Zepbounds active ingredient is tirzapetide and Wegovys is semaglutide
For diabetes management, if HbA1c remains above target despite maximal tirzepatide dosing, combination therapy with metformin, SGLT2 inhibitors, or basal insulin should be considered based on individual patient factors and contraindications
US$ 22.56
US$ 23.07
US$ 28.29
US$ 24.18
US$ 25.86
US$ 25.06
US$ 23.00
US$ 21.55
